首页> 外文期刊>BMC Pulmonary Medicine >Can severe asthmatic patients achieve asthma control? A systematic approach in patients with difficult to control asthma followed in a specialized clinic
【24h】

Can severe asthmatic patients achieve asthma control? A systematic approach in patients with difficult to control asthma followed in a specialized clinic

机译:重症哮喘患者可以控制哮喘吗?难以控制的哮喘患者的系统化治疗方法是在专门诊所进行

获取原文
           

摘要

Background Despite advances in asthma treatment, severe asthma (SA) still results in high morbidity and use of health resources. Our hypothesis was that SA patients would achieve adequate control with a systematic protocol, including oral corticosteroids, budesonide/formoterol maintenance and reliever therapy and a multidisciplinary approach to improve adherence. Methods Non-controlled (NC) SA patients were enrolled to receive 2?weeks of oral corticosteroids and 12?weeks of formoterol?+?budesonide. Assessments included asthma control questionnaire (ACQ), asthma control test (ACT), daily symptom diary, lung function and health-related quality of life (HRQoL) questionnaires. Results Of 51 patients, 13 (25.5%) achieved control. NC patients had higher utilization of health resources and higher exacerbation rates. Both controlled (C) and NC patients had significantly reduced ACQ scores after oral corticosteroid treatment. After 12?weeks, C patients continued improving. NC patients did not have significant changes. A similar pattern was found regarding lung function, use of rescue medication, and days free of symptoms. After 2?weeks of oral corticosteroids, an increase occurred in those who achieved the ACQ cut off; however, 53.8% of C patients had an ACQ?Conclusions Despite rigorous, optimized follow-up treatment, 75% of SA patients did not achieve adequate symptom control and presented with impaired quality of life. Conversely, application of a low-cost, easy to implement systematic protocol can prevent up to 25% of SA patients from up-titrating to new and complex therapies, thus reducing costs and morbidity. Trial registration Retrospectively registered at ClinicalTrial.gov on 22 February 2010 ( NCT01089322 ).
机译:背景技术尽管哮喘治疗取得了进步,但严重的哮喘(SA)仍然导致高发病率和对卫生资源的利用。我们的假设是SA患者可以通过系统的方案获得足够的控制,包括口服糖皮质激素,布地奈德/福莫特罗维持和缓解疗法以及采用多学科方法来改善依从性。方法纳入非对照(NC)SA患者,接受2周的口服糖皮质激素治疗和12周的福莫特罗+布地奈德治疗。评估包括哮喘控制问卷(ACQ),哮喘控制测试(ACT),每日症状日记,肺功能和健康相关生活质量(HRQoL)问卷。结果51例患者中,有13例(25.5%)获得了控制。 NC患者具有更高的卫生资源利用率和更高的恶化率。口服皮质类固醇激素治疗后,对照组(C)和NC患者的ACQ得分均明显降低。 12周后,C患者继续改善。 NC患者无明显变化。关于肺功能,使用急救药物和无症状天数也发现了类似的模式。口服皮质类固醇激素治疗2周后,达到ACQ临界值的人数增加了。然而,有53.8%的C患者有ACQ?结论尽管进行了严格,优化的随访治疗,但75%的SA患者仍未获得足够的症状控制,并且生活质量受损。相反,低成本,易于实施的系统方案的应用可以防止多达25%的SA患者适应新的复杂疗法,从而降低成本和发病率。试验注册于2010年2月22日在ClinicalTrial.gov上进行回顾性注册(NCT01089322)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号